立方制药(003020) - 立方制药调研活动信息(2)

Group 1: Product Development and Approval - The company is in the final negotiation stage for a significant growth opportunity related to the acquisition of ophthalmic drugs, with a focus on promoting specific eye drop products like "Jin Zhen" and "Pyridostatin Potassium" [1] - The approval for "Nifedipine Controlled-Release Tablets" has been submitted and is expected to be approved this year after passing the production site inspection in March [1] - The production capacity for "Yiqi Hewei Capsules" is nearly saturated, with a new production line expected to be operational in the second half of the year [1] Group 2: Market Strategy and Sales Growth - The company aims to increase its investment in ophthalmic formulation R&D and plans to establish its own ophthalmic production line [1] - The growth potential for essential drugs in hospitals remains significant, with a target for basic drug distribution in healthcare institutions to reach at least 90% [1] - The sales channels for "Clindamycin Gel" include both hospitals and retail [2] Group 3: Business Focus and Future Planning - The company will continue to focus on its pharmaceutical industrial sector while improving the operational quality of its pharmaceutical commercial segment, primarily within the province [4]